专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07988965B2 Methods of treating systemic lupus erythematosus with an antibody against costimulatory signal transduction molecule ailim 失效
标题翻译：用针对共刺激信号转导分子的抗体治疗系统性红斑狼疮的方法
公开(公告)号：US07988965B2
公开(公告)日：2011-08-02
申请号：US11752659
申请日：2007-05-23
申请人： Takashi Tsuji , Katsunari Tezuka , Nobuaki Hori
发明人： Takashi Tsuji , Katsunari Tezuka , Nobuaki Hori
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , A01K2217/05 , A61K2039/505 , C07K16/28 , C07K16/2818 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C07K2319/30
摘要： Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.
摘要翻译：用AILIM分子作为抗原，使用基因工程技术产生的产生抗体的转基因小鼠的免疫导致能够结合AILIM并能够控制多种生物反应的各种人单克隆抗体（例如，细胞增殖，细胞因子产生，免疫细胞溶解，细胞死亡，诱导ADCC等）与AILIM介导的共刺激信号（二级信号）转导相关。此外，已经揭示了人单克隆抗体有效治疗和预防与AILIM介导的共刺激信号转导相关的各种疾病，能够抑制疾病的发病和/或进展。

2. 发明授权

US06803039B2 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM 有权
标题翻译：针对共刺激信号转导分子AILIM的人单克隆抗体
公开(公告)号：US06803039B2
公开(公告)日：2004-10-12
申请号：US09859053
申请日：2001-05-16
申请人： Takashi Tsuji , Katsunari Tezuka , Nobuaki Hori
发明人： Takashi Tsuji , Katsunari Tezuka , Nobuaki Hori
IPC分类号： A61K39395
CPC分类号： C07K16/18 , A01K2217/05 , A61K2039/505 , C07K16/28 , C07K16/2818 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C07K2319/30
摘要： Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.
摘要翻译：用AILIM分子作为抗原，使用基因工程技术产生的产生抗体的转基因小鼠的免疫导致能够结合AILIM并能够控制多种生物反应的各种人单克隆抗体（例如，细胞增殖，细胞因子产生，免疫细胞溶解，细胞死亡，诱导ADCC等）与AILIM介导的共刺激信号（二级信号）转导相关。此外，已经揭示了人单克隆抗体有效治疗和预防与AILIM介导的共刺激信号转导相关的各种疾病，能够抑制疾病的发病和/或进展。

3. 发明授权

US06677138B2 Production of a multimeric protein by cell fusion method 有权
标题翻译：通过细胞融合法制备多聚体蛋白
公开(公告)号：US06677138B2
公开(公告)日：2004-01-13
申请号：US09945387
申请日：2001-08-30
申请人： Nobuaki Hori , Claude Geoffrey Davis , Krisztina M. Zsebo , Aya Jakobovits
发明人： Nobuaki Hori , Claude Geoffrey Davis , Krisztina M. Zsebo , Aya Jakobovits
IPC分类号： C12P2104
CPC分类号： C07K14/00 , C07K16/00 , C07K16/244 , C07K2317/21 , C12N5/16 , C12N5/166 , C12N15/62 , C12N2510/02
摘要： The present invention features a method of producing a multimeric protein from a hybrid cell formed from the fusion of two or more cells, each of which cell is engineered to express one component of the multimeric protein, as well as a method for screening for successful fusion of the cells to produce a desired hybrid cell. The methods of the invention are widely applicable to the production of proteins having two or more components.
摘要翻译：本发明的特征在于从由两个或多个细胞的融合形成的杂交细胞产生多聚体蛋白质的方法，每个细胞被工程化以表达多聚体蛋白质的一个组分，以及筛选成功融合的方法的细胞以产生所需的杂交细胞。本发明的方法可广泛用于生产具有两种或多种组分的蛋白质。

4. 发明申请

US20100145298A1 OXYGEN-CARRYING BLOOD SUBSTITUTE PREPARATIONS 审中-公开
标题翻译：氧气替代血液制剂
公开(公告)号：US20100145298A1
公开(公告)日：2010-06-10
申请号：US12704700
申请日：2010-02-12
申请人： Nobuaki HORI , Yoshihisa Manabe , Yuko Suka , Toshiya Kai , Seiji Nishida , Naohisa Katayama
发明人： Nobuaki HORI , Yoshihisa Manabe , Yuko Suka , Toshiya Kai , Seiji Nishida , Naohisa Katayama
IPC分类号： A61J1/10
CPC分类号： A61K47/183 , A61K9/1271 , A61K9/1272 , A61K38/41 , A61K38/42 , A61K47/12 , A61K47/24
摘要： An oxygen-carrying blood substitute preparation stable upon storage is provided. The preparation comprises an oxygen-carrying substance capable of reversibly binding and releasing oxygen in vivo and an amount of a physiologically tolerable reducing agent effective for preventing at least partially irreversible oxidation of said oxygen-carrying substance. Preferably the oxygen-carrying substance is a hemoglobin-based substance in the form of a liposome encapsulating hemoglobin.
摘要翻译：提供了一种在储存时稳定的载氧血液替代物制剂。该制剂包含能够在体内可逆地结合和释放氧的携氧物质以及有效预防所述携氧物质的至少部分不可逆氧化的生理上可耐受的还原剂的量。优选地，携氧物质是包封血红蛋白的脂质体形式的基于血红蛋白的物质。

5. 发明授权

US5467898A Liquid foam-discharging, squeezable vessel 失效
标题翻译：液体泡沫排放，可挤压容器
公开(公告)号：US5467898A
公开(公告)日：1995-11-21
申请号：US329790
申请日：1994-10-27
申请人： Nobuaki Hori
发明人： Nobuaki Hori
IPC分类号： B05B7/00 , B05B11/00 , B05B11/04
CPC分类号： B05B7/0037 , B05B11/0029 , B05B11/043 , B05B7/0018
摘要： A liquid foam-discharging, squeezable bottle is disclosed, which has a twist cap screwed onto the vessel body, the twist cap being composed of an inner cap and outer cap. The inner cap has formed therein two independent fluid-passing mechanisms at about its central position and at a position adjacent thereto, respectively. One of the fluid-passing mechanism is a liquid foam-generating mechanism comprising a pipe-shaped member having a net screen on one end thereof, and the other functions as a check valve. The outer cap has engaged inside of the foam-discharging opening an adapter fully covered with a net screen on one end located nearer to the contents of the vessel. This vessel enables one to rapidly discharge a uniform, creamy liquid foam by simple squeezing operation and, if desired, the foam can be sprayed by using an adapter having a small-diameter nozzle.
摘要翻译：公开了一种液体泡沫排出挤压瓶，其具有拧在容器主体上的扭转帽，扭转帽由内盖和外盖组成。内盖在其中心位置和与其相邻的位置处分别形成有两个独立的流体通过机构。流体通过机构之一是液体发泡机构，其包括在其一端具有网状筛网的管状部件，另一方面作为止回阀。外盖已经在泡沫排放开口的内部接合，该适配器在位于更靠近容器的内容物的一端处被完全覆盖有网筛的适配器。该容器使得能够通过简单的挤压操作快速排出均匀的奶油状液体泡沫，并且如果需要，可以通过使用具有小直径喷嘴的适配器喷射泡沫。

6. 发明授权

US07429380B2 Production of a multimeric protein by cell fusion method 有权
标题翻译：通过细胞融合法制备多聚体蛋白
公开(公告)号：US07429380B2
公开(公告)日：2008-09-30
申请号：US10719006
申请日：2003-11-20
申请人： Nobuaki Hori , Claude Geoffrey Davis , Krisztina M. Zsebo , Aya Jakobovits
发明人： Nobuaki Hori , Claude Geoffrey Davis , Krisztina M. Zsebo , Aya Jakobovits
IPC分类号： A61K39/00
CPC分类号： C07K14/00 , C07K16/00 , C07K16/244 , C07K2317/21 , C12N5/16 , C12N5/166 , C12N15/62 , C12N2510/02
摘要： The present invention features a method of producing a multimeric protein from a hybrid cell formed from the fusion of two or more cells, each of which cell is engineered to express one component of the multimeric protein, as well as a method for screening for successful fusion of the cells to produce a desired hybrid cell. The methods of the invention are widely applicable to the production of proteins having two or more components.
摘要翻译：本发明的特征在于从由两个或多个细胞的融合形成的杂交细胞产生多聚体蛋白质的方法，每个细胞被工程化以表达多聚体蛋白质的一个组分，以及筛选成功融合的方法的细胞以产生所需的杂交细胞。本发明的方法可广泛用于生产具有两种或多种组分的蛋白质。

7. 发明申请

US20080199466A1 HUMAN MONOCLONAL ANTIBODY AGAINST A COSTIMULATORY SIGNAL TRANSDUCTION MOLECULE AILIM AND PHARMACEUTICAL USE THEREOF 失效
标题翻译：人体单抗抗体信号转导分子AILIM及其药物应用
公开(公告)号：US20080199466A1
公开(公告)日：2008-08-21
申请号：US11752659
申请日：2007-05-23
申请人： Takashi Tsuji , Katsunari Tezuka , Nobuaki Hori
发明人： Takashi Tsuji , Katsunari Tezuka , Nobuaki Hori
IPC分类号： A61K39/395 , C07K16/18 , C07H21/04 , C12N15/00 , G01N33/566 , A61K31/7088 , C12N5/00 , C12N5/06
CPC分类号： C07K16/18 , A01K2217/05 , A61K2039/505 , C07K16/28 , C07K16/2818 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C07K2319/30
摘要： Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.
摘要翻译：用AILIM分子作为抗原，使用基因工程技术产生的产生抗体的转基因小鼠的免疫导致能够结合AILIM并能够控制多种生物反应的各种人单克隆抗体（例如，细胞增殖，细胞因子产生，免疫细胞溶解，细胞死亡，诱导ADCC等）与AILIM介导的共刺激信号（二级信号）转导相关。此外，已经揭示了人单克隆抗体有效治疗和预防与AILIM介导的共刺激信号转导相关的各种疾病，能够抑制疾病的发病和/或进展。

8. 发明授权

US07166283B2 Methods of treating an inflammatory disorder and prohibiting proliferation, cytokine production, and signal transduction with antibody against costimulatory signal transduction molecule AILIM 有权
标题翻译：治疗炎性疾病并禁止增殖，细胞因子产生和信号转导的方法，用抗共刺激信号转导分子AILIM
公开(公告)号：US07166283B2
公开(公告)日：2007-01-23
申请号：US10625105
申请日：2003-07-22
申请人： Takashi Tsuji , Katsunari Tezuka , Nobuaki Hori
发明人： Takashi Tsuji , Katsunari Tezuka , Nobuaki Hori
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/18 , A01K2217/05 , A61K2039/505 , C07K16/28 , C07K16/2818 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C07K2319/30
摘要： Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.
摘要翻译：用AILIM分子作为抗原，使用基因工程技术产生的产生抗体的转基因小鼠的免疫导致能够结合AILIM并能够控制多种生物反应的各种人单克隆抗体（例如，细胞增殖，细胞因子产生，免疫细胞溶解，细胞死亡，诱导ADCC等）与AILIM介导的共刺激信号（二级信号）转导相关。此外，已经揭示了人单克隆抗体有效治疗和预防与AILIM介导的共刺激信号转导相关的各种疾病，能够抑制疾病的发病和/或进展。

9. 发明授权

US06518235B1 Methods for improving brain function using leptin or analogs thereof 失效
标题翻译：使用瘦素或其类似物改善脑功能的方法
公开(公告)号：US06518235B1
公开(公告)日：2003-02-11
申请号：US09200919
申请日：1998-11-30
申请人： Yutaka Oomura , Nobuaki Hori , Takemasa Shiraishi , Kazuo Sasaki , Hiroshi Takeda , Minoru Tsuji , Teruhiko Matsumiya
发明人： Yutaka Oomura , Nobuaki Hori , Takemasa Shiraishi , Kazuo Sasaki , Hiroshi Takeda , Minoru Tsuji , Teruhiko Matsumiya
IPC分类号： A01N3718
CPC分类号： C07K14/5759 , A61K38/2264
摘要： The present invention is to provide a drug for improvement of brain function which is effective to prevent from or to cure dementia such as Alzheimer's disease. The drug for improvement of brain function of this invention comprises leptin of mammals as an effective component wherefore has a superior effect in improvement of learning and memory.
摘要翻译：本发明提供一种改善脑功能的药物，其有效地防止或治愈诸如阿尔茨海默病的痴呆症。用于改善本发明的脑功能的药物包括哺乳动物的瘦素作为有效成分，因此在改善学习和记忆方面具有优异的效果。

10. 发明申请

US20080193516A1 OXYGEN-CARRYING BLOOD SUBSTITUTE PREPARATIONS 审中-公开
标题翻译：氧气替代血液制剂
公开(公告)号：US20080193516A1
公开(公告)日：2008-08-14
申请号：US12031376
申请日：2008-02-14
申请人： Nobuaki HORI , Yoshihisa Manabe , Yuko Suka , Toshiya Kai , Seiji Nishida , Naohisa Katayama
发明人： Nobuaki HORI , Yoshihisa Manabe , Yuko Suka , Toshiya Kai , Seiji Nishida , Naohisa Katayama
IPC分类号： A61K9/127 , A61K38/41 , A61P7/00 , A61K31/555
CPC分类号： A61K47/183 , A61K9/1271 , A61K9/1272 , A61K38/41 , A61K38/42 , A61K47/12 , A61K47/24
摘要： An oxygen-carrying blood substitute preparation stable upon storage is provided. The preparation comprises an oxygen-carrying substance capable of reversibly binding and releasing oxygen in vivo and an amount of a physiologically tolerable reducing agent effective for preventing at least partially irreversible oxidation of said oxygen-carrying substance. Preferably the oxygen-carrying substance is a hemoglobin-based substance in the form of a liposome encapsulating hemoglobin.
摘要翻译：提供了一种在储存时稳定的载氧血液替代物制剂。该制剂包含能够在体内可逆地结合和释放氧的携氧物质以及有效预防所述携氧物质的至少部分不可逆氧化的生理上可耐受的还原剂的量。优选地，携氧物质是包封血红蛋白的脂质体形式的基于血红蛋白的物质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式